anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:The substituted vinylcarboxylic acid derivative of formula I [R<1> is phenyl or thienyl which may have alkoxy, alkyl, halogen, CF3 or methylenedioxy groups as substituent groups; R<2> is H or alkyl; one of R<3> and R<4> is H or alkyl and the other is H, alkyl or phenyl; n is 2-6]. EXAMPLE:(E)-7-Phenyl-7-(3-pyridyl)-6-heptenoic acid. USE:A drug having excellent action to inhibit specifically thromboxane-A2 synthesis enzyme. PROCESS:The compound of formula I can be prepared by heating the compound of formula II in the presence of a mineral acid. The starting compound of formula II is obtained e.g. by reacting the compound of formula III with the compound of formula IV in the presence of a base.
This invention supplies a series of production techniques of gene recombination live vaccine of swine virus contagion with canine II adenovirus as carrier and finished goods. The viral live vectors vaccine takes swine important virus zymad protective antigens gene as object gene, which are chosen from HCV-E1, E2 gene, FMDV-VP1,VP2,VP3,VP4 gene, TGEV-S,N,M gene, PEDV-S,N,M gene,SIV-HA,NA gene,RV-G,N gene, etc. The produced vaccines contain recombined swine influenza virus HA gene adenovirus carrier live vaccine, swine plague virus E2 gene adenovirus carrier live vaccine and recombination swine AsiaI foot-and-mouth disease virus VPI gene adenovirus carrier live vaccine. Recombination virus has good inheritance stability, and vaccine immunization can induct pig develop differential antiviral neutralization antibody. It has good immune protection effect and has no toxic side effect. The goods are facilitating for preserve and transport;it has long storage life and simple technics, and it fits for commercial manufacture.
The present invention relates to L53 genes and gene products that are differentially expressed in cancer tissues and cell lines. In a particular aspect of the invention, L53 genes and gene products are differentially expressed in lung cancer tissues and cell lines. In accordance with the present invention, L53 nucleic acid sequences, amino acid sequences and antibodies thereto, and methods of use thereof are presented. The L53 molecules and methods of the invention may be used to monitor expression levels of L53, wherein the detection of aberrant levels of L53 molecules provides a positive diagnostic indicator of lung cancer and/or other L53 associated cancers and a useful prognostic indice of the state of the diseases. Also provided are compounds capable of modulating L53 activity, which are identified using the L53 molecules and methods of the invention. Such L53 modulating compounds may be used efficaciously to treat patients with lung cancer, or other L53 antigen positive cancers.
Interleukin 1 is purified to homogeneity by use of various techniques including ion exchange chromatography and dye-ligand affinity chromatography, thereby enabling the amino acid composition of this protein to be ascertained and its amino acid sequence to be partially determined.  Double-stranded cDNA is prepared from polyadenylated RNA extracted from activated human peripheral blood adherent mononuclear cells. The cDNA is inserted within a plasmid vector and then the recombinant plasmid employed to transform an appropriate host. Plasmid DNA prepared from pools of transformed hosts is hybridized with a labeled, synthetic oligonucleotide probe corresponding to a portion of the ascertained amino acid sequence of the interleukin 1 protein. Pools of host cells that provide a positive signal to the probe are identified, plated out and then employed in direct bacterial colony hybridization with the same probe, thereby to isolate the particular positive colony. Plasmid DNA is prepared from this colony and characterized by restriction enzyme mapping and sequenced. The coding region for the IL-1 gene is inserted into a shuttle vector for amplification of the vector followed by expression of functional IL-1.
Hair cells in the cochlear sensory epithelia serve as mechanosensory receptors, converting sound into neuronal signals. The basal sensory epithelia are responsible for transducing high-frequency sounds, while the apex handles low-frequency sounds. Age-related hearing loss predominantly affects hearing at high frequencies and is indicative of damage to the basal sensory epithelia. However, the precise mechanism underlying this site-selective injury remains unclear. In this study, we employed a microscale proteomics approach to examine and compare protein expression in different regions of the cochlear sensory epithelia (upper half and lower half) in 1.5-month-old (normal hearing) and 6-month-old (severe high-frequency hearing loss without hair cell loss) C57BL/6J mice. A total of 2,386 proteins were detected, and no significant differences in protein expression were detected in the upper half of the cochlear sensory epithelia between the two age groups. The expression of 20 proteins in the lower half of the cochlear sensory epithelia significantly differed between the two age groups (e.g., MATN1, MATN4, and AQP1). Moreover, there were 311 and 226 differentially expressed proteins between the upper and lower halves of the cochlear sensory epithelia in 1.5-month-old and 6-month-old mice, respectively. The expression levels of selected proteins were validated by Western blotting. These findings suggest that the spatial differences in protein expression within the cochlear sensory epithelia may play a role in determining the susceptibility of cells at different sites of the cochlea to age-related damage.
Severe dermatologic reactions such as toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), and linear IgA bullous dermatosis (LABD) have been reported in association with the use of vancomycin. Cutaneous signs or symptoms reported include skin rashes, mucosal lesions, and blisters. 

Discontinue vancomycin hydrochloride at the first appearance of signs and symptoms of TEN, SJS, DRESS, AGEP, or LABD.

Clostridium Difficile Associated Diarrhea (CDAD)

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Vancomycin Hydrochloride for Injection, USP, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. 

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. 

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated. 

Hemorrhagic Occlusive Retinal Vasculitis (HORV) 

Hemorrhagic occlusive retinal vasculitis, including permanent loss of vision, occurred in patients receiving intracameral or intravitreal administration of vancomycin during or after cataract surgery. The safety and efficacy of vancomycin administered by the intracameral or the intravitreal route have not been established by adequate and well-controlled trials. Vancomycin is not indicated for the prophylaxis of endophthalmitis.
The invention provides a grapefruit radish facial cleanser. According to the invention, grapefruit slurry manufactured from grapefruit peels, radish juice, pearl liquid, and auxiliary materials such as a surfactant are subject to processes such as emulsifying, mixing, regulating, filtering, grinding, and aging, such that the facial cleanser is obtained. Radish contains an antibiotic substance raphanin, such that radish has good inhibiting effects against various dermatophytes. Also, radish has functions of inflammation eliminating and stagnated blood dissipating. Grapefruit contains naringin with an aging-resisting effect. The facial cleanser provided by the invention is a product developed with grapefruit slurry and radish juice as main materials. Potencies of the two cooperate with each other, and the auxiliary material pearl nutrient solution is adopted, such that skin-protecting and disease-treating effects are improved. As results of trials, the facial cleanser provides substantial effects of macule removing, acne removing and whitening. The facial cleanser is a product with good developing prospect.
PURPOSE:To efficiently obtain a drug efficacious substance, having antitussive, germicidal and antifungal action, etc., and efficacious for malignant tumor, by crushing leaves and stalks of bamboo grass as a raw material into chips, steaming or boiling and hydrolyzing the chips at a high temperature under a high pressure and concentrating and drying the resultant extract solution. CONSTITUTION:Leaves and stalks of bamboo grass, e.g. Sasa kurilensis Makino, Sasa cerenua Makino, Sasa nipponica Makino et Shibata, Sasa paniculata Makino et Shibata, Sasa senanensis Rehder, Pseudosasa owatarii Makino, Sasa albo-marganinata Makino et Shibata or Pseudosasa purpurascens Makino, are crushed into chips having several cm length and treated with saturated steam at 180-200 deg.C under 16-20kg/cm<2> pressure in a boiling cooker for 10-20min. After the hydrolysis, the chips are dipped in hot water at 80-100 deg.C to partially remove lignin and cellulose in the raw material components and give solubilized hemicellulose in the residual hot water. The components in the hot water extract are saccharides constituted of xylose (80%), arabinose, glucose, mannose and glucose, which become drug efficacious components. The resultant drug efficacious substance has remarkable activating effect on metabolism of human tissues.
A 12 week pilot trial will be conducted at two rural food pantries in Montana with 40 low-income adults to measure within-participant changes over time. The study will provide the initial investigation of the extent to which UP3 will improve overall dietary quality as measured by the Healthy Eating Index-2015 (HEI) compared to baseline. Psychosocial factors will be measured to understand changes in knowledge, attitudes, and perceptions about processed foods. Data on biomarkers of health (i.e., weight, systolic blood pressure, HbA1c, fasting lipid panel) will be collected to assess the feasibility of measuring potential short-term health effects of UP3.
OBJECTIVE: The aim was to investigate the intergenerational inheritance induced by a high-fat diet on sensitivity to insulin and leptin in the hypothalamic control of satiety in second-generation offspring, which were fed a control diet.
METHODS: Progenitor rats were fed a high-fat or a control diet for 59 d until weaning. The first-generation and second-generation offspring were fed the control diet until 90 d of age. Body mass and adiposity index of the progenitors fed the high-fat diet and the second-generation offspring from progenitors fed the high-fat diet were evaluated as were the gene expression of DNA methyltransferase 3a, angiotensin-converting enzyme type 2, angiotensin II type 2 receptor, insulin and leptin signaling pathway (insulin receptor, leptin receptor, insulin receptor substrate 2, protein kinase B, signal transducer and transcriptional activator 3, pro-opiomelanocortin, and neuropeptide Agouti-related protein), superoxide dismutase activity, and the concentration of carbonyl protein and satiety-regulating neuropeptides, pro-opiomelanocortin and neuropeptide Agouti-related protein, in the hypothalamus.
RESULTS: The progenitor group fed a high-fat diet showed increased insulin resistance and reduced insulin-secreting beta-cell function and reduced food intake, without changes in caloric intake. The second-generation offspring from progenitors fed a high-fat diet, compared with second-generation offspring from progenitors fed a control diet group, had decreased insulin-secreting beta-cell function and increased food and caloric intake, insulin resistance, body mass, and adiposity index. Furthermore, second-generation offspring from progenitors fed a high-fat diet had increased DNA methyltransferase 3a, neuropeptide Agouti-related protein, angiotensin II type 1 receptor, and nicotinamide adenine dinucleotide phosphate oxidase p47phox gene expression, superoxide dismutase activity, and neuropeptide Agouti-related protein concentration in the hypothalamus. In addition, there were reduced in gene expression of the insulin receptor, leptin receptor, insulin receptor substrate 2, pro-opiomelanocortin, angiotensin II type 2 receptor, angiotensin-converting enzyme type 2, and angiotensin-(1-7) receptor and pro-opiomelanocortin concentration in the second-generation offspring from progenitors fed the high-fat diet.
CONCLUSIONS: Overall, progenitors fed a high-fat diet induced changes in the hypothalamic control of satiety of the second-generation offspring from progenitors fed the high-fat diet through intergenerational inheritance. These changes led to hyperphagia, alterations in the hypothalamic pathways of insulin, and leptin and adiposity index increase, favoring the occurrence of different cardiometabolic disorders in the second-generation offspring from progenitors fed the high-fat diet fed only with the control diet.
Patients were administered OTQ923 while enrolled on the treatment protocol (CADPT03A12101). Enrolled patients on this study will not be administered any study treatment.
Running exercise has been shown to alleviate depressive symptoms. However, the mechanism underlying the antidepressant effects of running exercise is not fully understood. The imbalance of M1/M2 microglia phenotype/polarization and concomitant dysregulation of neuroinflammation play crucial roles in the pathogenesis of depression. Running exercise increases circulating levels of adiponectin which is known to cross the blood‒brain barrier and suppress inflammatory responses. AdipoR1 is an adiponectin receptor that is involved in regulating microglial phenotypes and activation states. However, whether running exercise regulates hippocampal microglial phenotypes and neuroinflammation through adiponectin/AdipoR1 to exert its antidepressant effects remains unclear. In the current study, 4 weeks of running exercise significantly alleviated the depressive-like behaviors of chronic unpredictable stress (CUS)-exposed mice. Moreover, running exercise decreased the microglial numbers and altered microglial morphology in three subregions of the hippocampus to restore the M1/M2 balance; these effects were accompanied by regulation of pro-/anti-inflammatory cytokine production and secretion in CUS-exposed mice. These effects may involve elevation of peripheral tissue (adipose tissue and muscle) and plasma adiponectin levels, and hippocampal AdipoR1 levels as well as activation of the AMPK-NF-κB/STAT3 signaling pathway by running exercise. When an adeno-associated virus was used to knock down hippocampal AdipoR1, mice showed depressive-like behaviors and alterations in microglia and inflammatory factor expression in the hippocampus that were similar to those observed in CUS-exposed mice. Together, these results suggest that running exercise maintains the M1/M2 balance and inhibits neuroinflammation in the hippocampus of CUS-exposed mice. These effects might occur via adiponectin/AdipoR1-mediated activation of the AMPK-NF-κB/STAT3 signaling pathway.
Myocardial fibrosis is a key pathological mechanism in HFpEF. Pirfenidone is an anti-fibrotic medication licensed for the treatment of idiopathic lung fibrosis, for which it reduces lung function decline, improves progression free survival and reduces all cause mortality. In pre-clinical models, pirfenidone attenuates profibrotic pathways and is associated with regression of myocardial fibrosis. Previous studies in HFpEF populations using anti-fibrotic medications, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II receptor blockers and aldosterone antagonists have shown some benefit in reaching secondary end-points but do not reduce mortality. HFpEF is the final result of a number of specific underlying pathological mechanisms, and targeted treatment of these mechanisms has been cited as the future approach to further clinical trials. The investigators aim to select a population of HFpEF patients with high levels of interstitial myocardial fibrosis as measured on cardiac MRI (CMR), and randomise participants to receive pirfenidone or placebo. The primary outcome is to detect a significant reduction in myocardial fibrosis as measured on CMR after 12 months of intervention.
A method is described for enhancing arteriogenesis in animals with comorbidities commonly found in patients with ischemic disease, and in animals with a genetically-impaired arteriogenesis response. Administration to an animal of satellite derived myoblasts increases maximum diameter of collateral arteries. In embodiments, the animal is an obese animal or an animal having impaired arteriogenesis due to genetic variation causing the phenotype. The administration of such myoblasts to a non-obese animal does not increase maximum diameter of the animal's collateral arteries. Blood flow is increased, and ischemia is decreased. Compositions and kits comprising the myoblasts are also provided.
The invention relates to the technical field of veterinary drug, and discloses a Chinese medicine transdermal ointment for external application to remedy cow mastitis and a preparation method thereof. The transdermal ointment is well-proportioned oil/water (o/w) cream prepared from 25 to 40 percent of the extract of taraxacum, scutellaria and forsythia, 1 to 6 percent of transdermal penetration enhancer and 74 to 54 percent of drug matrix. The invention uses the administration manner of being smeared for transdermal absorption to remedy the cow mastitis. The preparation can permeate skin and has partial treatment effect in galactopore, which has convenient administration, good antibiosis and antiphlogosis effect, no toxin, irritation and anaphylactic reaction. The invention can not only avoid the problems of oral administration, muscle injection and lacteal cistern perfusion but also avoid the bad reactions of hangover and drug resistance, which are aroused by antibiotic. The clinicaltreatment results indicate that the transdermal ointment has good treatment effect on clinical mastitis and recessive mastitis without influencing the milk quality.
Devices, processes and compositions are provided for effective separation of cells from a mixture of cells, where depletion or positive selection may be employed to provide a cellular population of interest.  Of particular utility is the separation of cells from peripheral blood mononuclear cells, where members of the lymphoid or myeloid lineages may be isolated and used for research, diagnosis or therapy. Also of interest are cellular separation from bone marrow, tumor suspensions or lymphoid tissue suspensions, where cells can be isolated and used for a variety of purposes.  The separated cells may be homogeneous, free of exogenous biologicals, viable, capable of replication and exhibit their full complement of biological activities.  Multiple phenotypes can be captured simultaneously.  Captured cells can be specifically activated with cytokines and antigens to provide cells which are MHC restricted and have antigen-specific effector functions.
Identifying women with a history of cesarean delivery and at real risk for uterine rupture is an important aim in obstetric care. It is with this objective that different authors have evaluated the interest of ultrasound for predicting the risk of a cesarean scar defect by measuring the thickness of the lower uterine segment. The literature is sparse and subject to numerous biases because they are mainly prospective cohort studies with small numbers. However, the results are concordant: Ultrasound measurements of lower uterine segment thickness are strongly correlated with the operative findings observed during cesarean delivery. Moreover, the thinner the lower uterine segment on ultrasound, the higher the likelihood of a uterine defect. Two randomized trials have recently been published. The PRISMA cluster randomized controlled trial evaluated a multifaceted intervention including an ultrasound estimation of the risk of uterine rupture by ultrasound measurement of the lower uterine segment thickness and aimed at helping women in their choice of mode of delivery after a previous cesarean delivery. This multifaceted intervention resulted in a significant reduction in the rates of major perinatal and maternal morbidity, without any increase in the rate of cesarean delivery or uterine rupture. However, due to its design, it is impossible to specifically specify the benefit of lower uterine segment measurement in reducing major maternal and perinatal morbidity since the trial combined several interventions. The LUSTrial randomized controlled trial evaluated the impact on maternal-fetal morbidity and mortality of proposing a mode of delivery based on ultrasound measurement of the lower uterine segment thickness compared to usual care among women with a history of cesarean delivery. Ultrasound measurement of lower uterine segment thickness was not associated with a statistically significant reduction in maternal-fetal morbidity and mortality compared to usual care. In this literature review, we will mainly detail and analyze the results of this trial.
Clinical trials have demonstrated that anti-IL-1 agents (IL-1Ra, IL-1 Trap, and anti-IL-1β monoclonal antibody) can reduce the frequency of gout flares during the initial period of treatment with urate-lowering therapy and prevent of gout flares in gout patients with frequent flares. AC-201 is an oral IL-1 modulator but with a mechanism distinct from that of existing anti-IL-1 agents. The active metabolite of AC-201 has been shown in vitro and in vivo to inhibit the production and activity of IL-1, down-regulate IL-1 receptors, and increase IL1-Ra. Molecular research further suggests that these effects are mediated upstream via inhibition of MAPK signaling pathways and binding of NF-κB and AP-1 transcription factors that encode for a range of pro-inflammatory factors, including IL-1β, TNF-α, IL-6, IL-8, iNOS, and MMPs, which have been implicated in gout flares. AC-201 has also been demonstrated to have uric acid-lowering effects in clinical trials. The favorable product profile of AC-201 overall provides a strong rationale for investigating its clinical utility as prophylaxis against flares when initiating ULT.